Identification of a New Hormone-Binding Site on the Surface of Thyroid Hormone Receptor

Thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily of ligand-activated transcription factors involved in cell differentiation, growth, and homeostasis. Although X-ray structures of many nuclear receptor ligand-binding domains (LBDs) reveal that the ligand binds within th...

Full description

Saved in:
Bibliographic Details
Published inMolecular endocrinology (Baltimore, Md.) Vol. 28; no. 4; pp. 534 - 545
Main Authors Souza, P.C.T, Puhl, A.C, Martínez, L, Aparício, R, Nascimento, A.S, Figueira, A.C.M, Nguyen, P, Webb, P, Skaf, M.S, Polikarpov, I
Format Journal Article
LanguageEnglish
Published United States Endocrine Society 01.04.2014
Oxford University Press
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Thyroid hormone receptors (TRs) are members of the nuclear receptor superfamily of ligand-activated transcription factors involved in cell differentiation, growth, and homeostasis. Although X-ray structures of many nuclear receptor ligand-binding domains (LBDs) reveal that the ligand binds within the hydrophobic core of the ligand-binding pocket, a few studies suggest the possibility of ligands binding to other sites. Here, we report a new x-ray crystallographic structure of TR-LBD that shows a second binding site for T3 and T4 located between H9, H10, and H11 of the TRα LBD surface. Statistical multiple sequence analysis, site-directed mutagenesis, and cell transactivation assays indicate that residues of the second binding site could be important for the TR function. We also conducted molecular dynamics simulations to investigate ligand mobility and ligand-protein interaction for T3 and T4 bound to this new TR surface-binding site. Extensive molecular dynamics simulations designed to compute ligand-protein dissociation constant indicate that the binding affinities to this surface site are of the order of the plasma and intracellular concentrations of the thyroid hormones, suggesting that ligands may bind to this new binding site under physiological conditions. Therefore, the second binding site could be useful as a new target site for drug design and could modulate selectively TR functions.
Bibliography:This work was supported by Fundação de Amparo de Pesquisa do Estado de São Paulo (FAPESP) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). M.S.S. was supported through the CEPID Grant 2013/08293–7 from FAPESP. A.C.M.F. was supported by Grant 2010/17048–8 from FAPESP.
P.C.T.S. and A.C.P. made equal contributions to this work.
ISSN:0888-8809
1944-9917
DOI:10.1210/me.2013-1359